Thomas Brunner

Director / Prof.

Medical University of Graz

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Cancer Biology Cancer Biology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas Brunner is a Professor and Director at Medizinische Universität Graz, Austria. His research encompasses various aspects of oncology, particularly focusing on esophageal and colorectal cancers, as well as advanced radiotherapy techniques. Recent publications include studies on the recurrence patterns of esophageal adenocarcinoma, the prognostic factors in rectal cancer, and innovations in stereotactic body radiotherapy.

Articles (8)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

Tanja Langsenlehner

Medical University of Graz

AUSTRIA

View details

Christos Moustakis

Univ.-Prof.

Leipzig University

GERMANY

View details

Magdalena Huber

Prof. Dr.

Philipps-Universität Marburg

GERMANY

View details

Bjoern Menze

Professor

University of Zurich

SWITZERLAND

View details

Oliver Blanck

Chief Officer of Operations; Head of Medical Physics, Research and Development

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Brunner

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy

Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer

Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.

Identifying core MRI sequences for reliable automatic brain metastasis segmentation

The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer

The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner

125 years of head and neck radiotherapy: could organ-sparing radiotherapy of larynx cancer have prevented World War I?

FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro

Collaborators (5)

Tanja Langsenlehner

Christos Moustakis

Magdalena Huber

Bjoern Menze

Oliver Blanck

Make your next move.